PSTXPoseida Therapeutics, Inc.

Nasdaq poseida.com


$ 2.71 $ 0.00 (0 %)    

Thursday, 09-May-2024 15:59:55 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 2.71
$ 2.69
$ 0.00 x 0
$ 0.00 x 0
$ 2.64 - $ 2.71
$ 1.54 - $ 4.27
417,831
na
244.4M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-07-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-11-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-20-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 poseida-highlights-progress-on-its-genetic-medicine-programs-at-the-american-society-for-gene-and-cell-therapy-27th-annual-meeting

Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic rang...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

Core News & Articles

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...

 astellas-and-poseida-therapeutics-enter-into-research-collaboration-and-license-agreement-to-develop-novel-allogeneic-cell-therapies-in-oncology

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 poseida-therapeutics-presents-new-phase-1-data-at-aacr-2024-supporting-potential-of-p-bcma-allo1-allogeneic-car-t-therapy-to-benefit-broad-range-of-patients-with-multiple-myeloma

Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therap...

 why-mesoblast-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...

 eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

 hc-wainwright--co-reiterates-buy-on-poseida-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

 poseida-therapeutics-q4-eps-027-beats-039-estimate-sales-2500m-beat-665m-estimate

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of ...

 poseida-therapeutics-highlights-recent-progress-strategic-priorities-and-anticipated-2024-key-milestones

Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of TSCM...

 piper-sandler-maintains-overweight-on-poseida-therapeutics-raises-price-target-to-10

Piper Sandler analyst Edward Tenthoff maintains Poseida Therapeutics (NASDAQ:PSTX) with a Overweight and raises the price ta...

 poseida-therapeutics-new-treatment-for-multiple-myeloma-shows-early-success-in-clinical-trial

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its ...

Core News & Articles

PSTX: 73% | Poseida Therapeutics Presented Early Results From Its Phase 1 Trial Of Allogeneic CAR-T P-BCMA-ALLO1 In Relapsed-Re...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION